Today: 30 June 2026
ASML stock price jumps on AI-spending rebound — dividend dates and U.S. data ahead
8 February 2026
1 min read

ASML stock price jumps on AI-spending rebound — dividend dates and U.S. data ahead

Amsterdam, Feb 8, 2026, 01:03 (CET) — Market closed.

  • ASML shares rose 3.8% in Amsterdam on Friday; U.S.-listed shares gained 4.6%.
  • Chip stocks rallied as investors refocused on big tech spending for AI data centers.
  • Next week brings ASML’s ex-dividend dates and U.S. jobs and inflation reports.

ASML Holding NV shares ended Friday higher, closing up 3.84% at 1,193.80 euros in Amsterdam. The stock’s New York-listed shares closed up 4.6% at $1,413.01.

The move tracked a sharp rebound in chip stocks after investors latched onto fresh signals that big cloud groups plan to keep spending heavily on AI infrastructure. “I think there’s enough evidence that there’s real demand for AI products,” said Ross Mayfield, an investment strategy analyst at Baird. Reuters

ASML sits in the middle of that trade because it sells the lithography tools chipmakers use to print the most advanced circuits. It is “the only game in town” for extreme ultraviolet (EUV) lithography — the short-wavelength light technology used to make the tiniest features on leading-edge chips. Reuters

The company’s last earnings update still hangs over the tape. ASML reported record fourth-quarter net bookings — a measure of new orders — of 13.2 billion euros and lifted its 2026 sales outlook to 34 billion to 39 billion euros, while also flagging job cuts and a 12 billion euro share buyback plan. U.S.-led export restrictions still limit China’s access to its most advanced EUV tools, a swing factor for a market that has been a large buyer of chipmaking gear.

But the stock has also shown how quickly sentiment turns when expectations run hot. ASML shares trade at a rich multiple versus many peers, and investors keep circling the same questions: how fast ASML can lift output, and how much of the AI build-out is already priced in. “Much of the good news is then already priced in,” said Han Dieperink, chief investment officer at Aureus. Reuters

Next week brings a mechanical catalyst: ASML’s interim dividend. The stock is due to go ex-dividend — meaning buyers after that date won’t receive the payment — on Feb. 9 on Euronext Amsterdam and Feb. 10 on Nasdaq, with payment set for Feb. 18.

Macro is the other trigger. The U.S. employment report for January is scheduled for Feb. 11 and the January CPI inflation report for Feb. 13, data that can swing rate expectations and, by extension, valuations for high-growth tech and chip names.

With trading shut for the weekend, the immediate question is whether Friday’s bounce holds when Euronext reopens on Monday, especially with the dividend adjustment close behind.

For ASML, the week’s calendar is tight: ex-dividend in Amsterdam on Feb. 9, the U.S. jobs report on Feb. 11, and CPI on Feb. 13 — the next hard marker for the rates backdrop that has been whipsawing the AI trade.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Talawar Therapeutics to List Nasdaq as It Raises $285M for Atopic Dermatitis Drug
    June 30, 2026, 8:18 AM EDT. Talawar Therapeutics will go public on Nasdaq as 'TLWR' after pulling in $225 million through a PIPE plus $60 million from SPAC JATT II Acquisition, raising $285 million in total. The New Jersey biotech is developing TALA-125, an IL-13/IL-18 bispecific antibody aimed at atopic dermatitis, and is going up against Sanofi and Regeneron's top-selling Dupixent. Talawar says this new approach could get past limits of current therapies by targeting two immune pathways. The company expects to start Phase IIb trials by early 2027, with data coming in late 2028. AD sales could hit $22.4 billion by 2033, even as the field still sees unmet need.
Confluent stock edges higher as IBM deal vote nears after fresh merger filing
Previous Story

Confluent stock edges higher as IBM deal vote nears after fresh merger filing

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Next Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Go toTop